[HTML][HTML] Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria
JW Bennett, BS Pybus, A Yadava, D Tosh… - … England Journal of …, 2013 - Mass Medical Soc
JW Bennett, BS Pybus, A Yadava, D Tosh, JC Sousa, WF McCarthy, G Deye, V Melendez…
New England Journal of Medicine, 2013•Mass Medical SocPrimaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria | NEJM Skip to
main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare
to become a physician, build your knowledge, lead a health care organization, and advance
your career with NEJM Group information and services. NEJM Evidence NEW! A digital journal
for innovative original research and fresh, bold ideas in clinical trial design and clinical
decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to …
main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare
to become a physician, build your knowledge, lead a health care organization, and advance
your career with NEJM Group information and services. NEJM Evidence NEW! A digital journal
for innovative original research and fresh, bold ideas in clinical trial design and clinical
decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to …
Primaquine is used to eradicate the hepatic or hypnozoite form of Plasmodium vivax that may lead to relapse of infection. Host genetic factors may play a role in the activity of primaquine therapy.
The New England Journal Of Medicine